Clinical Trial

PROV-MESH: Prophylactic Ovarian Cancer MESH

Study acronym: PROV-MESH
Recruiting
View on ClinicalTrials.gov →
Summary
Incisional hernia is a common complication after midline laparotomy and may significantly impact quality of life, morbidity, and healthcare costs. Patients undergoing cytoreductive surgery for ovarian cancer are considered at increased risk due to extensive surgical procedures, nutritional status, and exposure to systemic treatments. This prospective randomized clinical trial aims to evaluate whether prophylactic mesh placement during abdominal wall closure reduces the incidence of incisional hernia compared with conventional fascial closure in women undergoing cytoreductive surgery for ovarian cancer through a midline laparotomy. To control for the potential effect of negative pressure wound therapy (NPWT) on surgical site infection, participants will also be randomized to receive NPWT or standard wound dressing, resulting in four treatment arms.
Trial Details
NCT Number NCT07676370
Lead Sponsor Hospital Vall d'Hebron
Collaborators: Germans Trias i Pujol Hospital, Fundación Jimenez Diaz de Madrid, Hospital Universitario La Fe
Conditions Ovarian Cancer
Enrollment 152 participants
Start Date 2026-01-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-30